Abstract
The utilization of vaccines to fight the spread of SARS-CoV-2 has led to a growing need for expansive serological testing. To address this, an EUA approved immunoassay for detection of antibodies to SARS-CoV-2 in venous serum samples was investigated for use with dried blood spot (DBS) samples. Results from self-collected DBS samples demonstrated a 98.1% categorical agreement to venous serum with a correlation (R) of 0.9600 while professionally collected DBS samples demonstrated a categorical agreement of 100.0% with a correlation of 0.9888 to venous serum. Additional studies were performed to stress aspects of at-home DBS collection, including shipping stability, interference effects, and other sample-specific robustness studies. These studies demonstrated a categorical agreement of at least 95.0% and a mean bias less than ±20.0%. Furthermore, the ability to track antibody levels following vaccination with the BioNTech/Pfizer vaccine was demonstrated with self-collected DBS samples from pre-dose (Day 0) out to 19 weeks.
Competing Interest Statement
PKM, BBC, and RPG are employees of Laboratory Corporation of America Holdings and participate in the employee stock purchase plan.
Funding Statement
This study was funded by Laboratory Corporation of America Holdings.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
IRB of ASPIRE (Protocol numbers: 520100174, 520180046) gave ethical approval of this work.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data produced in the present work are contained in the manuscript
12. Abbreviations
- CLSI
- Clinical and Laboratory Standards Institute
- CV
- Coefficient of variance
- DBS
- Dried Blood Spot
- DF
- Degrees of Freedom
- EUA
- Emergency Use Authorization
- FDA
- Food and Drug Administration
- MS
- Mean of Square
- n
- Number of replicates
- N
- Negative
- NA(or N/A)
- Not Applicable
- NPA
- Negative Predictive Agreement
- NTP
- No test performed
- NPV
- Negative Predictive Value
- P
- Positive
- PPA
- Positive Predictive Agreement
- PPV
- Positive Predictive Value
- QC
- Quality control
- SD
- Standard Deviation
- SS
- Sum of Squares
- U/mL
- Units per milliliter
